Targretin update

At the Hambrecht & Quist Life Sciences Conference today, LGND was to report interim results of a Phase I/II trial in KS. Seven of 46 patients (15 percent) met at least one AIDS Clinical Trial Group (ACTG) criterion for a partial response, compared to 3 of 46 (7 percent) control patients.

Three of 46 treated patients (7 percent) had partial responses, defined as a complete flattening of at least 50 percent of the raised treated lesions, versus 2 of 46 (4 percent) of untreated lesions. Four of 46 treated patients (9 percent) had partial responses, defined as a 50 percent or greater reduction in the sum of the areas of all treated lesions, versus 1 of 46 (2 percent) for the control lesions. ...